In this installment, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

CRISPR gene-editing technology presents a possible solution for feeding a growing population, but incorporating CRISPR into ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

CRISPR-Cas9 ... genome editing. Scientists argue that the technology involves considerable risk and uncertain benefits. Although compact Un1Cas12f1 has improved, low gene editing activity was ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...

If the company’s human leukocyte antigen (HLA ... is a clinical-stage biotechnology company developing gene-editing therapies using CRISPR technology to treat genetic disorders by modifying ...